Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

Keywords

AtezolizumabBevacizumabSunitinibMedicineRenal cell carcinomaOncologyHazard ratioInternal medicineProgression-free survivalNivolumabBlockadeImmunotherapyChromophobe cellConfidence intervalCancerOverall survivalClear cellChemotherapyReceptor

Affiliated Institutions

Related Publications

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn , Shukui Qin , Masafumi Ikeda +18 more

In patients with unresectable hepatocellular carcinoma, atezolizumab combined with bevacizumab resulted in better overall and progression-free survival outcomes than sorafenib. ...

2020 New England Journal of Medicine 6464 citations

Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma

Thomas Powles , Se Hoon Park , Éric Voog +24 more

Maintenance avelumab plus best supportive care significantly prolonged overall survival, as compared with best supportive care alone, among patients with urothelial cancer who h...

2020 New England Journal of Medicine 1374 citations

Advances in immunotherapy for hepatocellular carcinoma

Bruno Sangro , Pablo Sarobe , Sandra Hervás‐Stubbs +1 more

Hepatocellular carcinoma (HCC) is a prevalent disease with a progression that is modulated by the immune system. Systemic therapy is used in the advanced stage and until 2017 co...

2021 Nature Reviews Gastroenterology & Hep... 1220 citations

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Brian I. Rini , Elizabeth R. Plimack , V.P. Stus +24 more

Among patients with previously untreated advanced renal-cell carcinoma, treatment with pembrolizumab plus axitinib resulted in significantly longer overall survival and progress...

2019 New England Journal of Medicine 3200 citations

Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma

Jeffrey J. Wallin , Johanna C. Bendell , Roel Funke +19 more

Abstract Anti-tumour immune activation by checkpoint inhibitors leads to durable responses in a variety of cancers, but combination approaches are required to extend this benefi...

2016 Nature Communications 683 citations

Publication Info

Year: 2018
Type: article
Volume: 24
Issue: 6
Pages: 749-757
Citations: 1190
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

1190

OpenAlex

Cite This

APA Style

                            
                                
                                    David F. McDermott, 
                                
                                    Mahrukh Huseni, 
                                
                                    Michael B. Atkins
                                
                                et al.
                            
                            (2018). 
                            Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. 
                            Nature Medicine
                            , 24
                            (6)
                            , 749-757.
                            https://doi.org/10.1038/s41591-018-0053-3
                        

Identifiers

DOI: 10.1038/s41591-018-0053-3